tbuckley/cabot-search huggingface dataset:
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Authors: Smita Bhatia, Leslie L. Robison, Odile Oberlin, Mark Greenberg, Greta Bunin, Franca Fossati-Bellani, Anna T. Meadows
Journal: New England Journal of Medicine (1996)

Patients who survive Hodgkin's disease are at increased risk for second neoplasms. As survival times increase, solid tumors are emerging as a serious long-term complication.The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to determine the incidence of second neoplasms and the risk factors associated with them.In this cohort, there were 88 second neoplasms as compared with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidence interval, 14.3 to 22.3). The estimated actuarial incidence of any second neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent); the incidence of solid tumors was 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent). Breast cancer was the most common solid tumor (standardized incidence ratio 75.3; 95 percent confidence interval, 44.9 to 118.4), with an estimated actuarial incidence in women that approached 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) by 40 years of age. Older age (10 to 16 vs. <10 years) at the time of radiation treatment (relative risk, 1.9) and a higher dose (2000 to 4000 vs. <2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer. The estimated actuarial incidence of leukemia reached a plateau of 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent) 14 years after diagnosis. Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia.The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. Systematic screening for breast cancer could be important in the health care of such women.
PRETARGETED IMMUNOSCINTIGRAPHY WITH IN-111, GA-67 AND GA-68 LABELED BIVALENT (“JANUS”) HAPTENS.
Authors: David A Goodwin, Claude F Meares, Michael J McCall, Warak Chaovapong, Maureen McTigue, Carol I Diamanti
Journal: Clinical Nuclear Medicine (1988)

Goodwin, David A; Meares, Claude F; McCall, Michael J; Chaovapong, Warak; McTigue, Maureen; Diamanti, Carol I Author Information
Adiposis Dolorosa (Dercum's Disease)
Authors: William A. Steiger, Henry Litvin, E. M. Lasché, Thomas M. Durant
Journal: New England Journal of Medicine (1952)

IN 1892, Dercum1 described 3 patients from the wards of Blockley Hospital with a peculiar malady, which he entitled "adiposis dolorosa," a syndrome to which his name has subsequently been affixed. Although many cases of adiposis dolorosa have been described in the literature,2 , 3 4 5 little has been added in clinical description, pathophysiologic interpretation or etiologic definition since Dercum's original publication. It is our purpose to report, from the birthplace of this disease, another case of adiposis dolorosa in which special studies were performed.Adiposis dolorosa commonly affects menopausal women between the ages of thirty-five and fifty years. They are usually markedly . . .
AB0670 Prevalence of chronic back pain and inflammatory back pain in cohort young lithuanian people
Authors: J. Sabaliauskiene, A. Baranauskaite
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Inflammatory back pain (IBP) is one of the main presenting symptoms in spondyloarthropathies (SpA). The prevalence of inflammatory back pain in young people population is unknown. The identification of chronic IBP, starting before age 45 can help diagnose SpA early. <h3>Objectives</h3> To determine the prevalence of chronic low back pain and inflammatory back pain in a cohort of young people. <h3>Methods</h3> Students were asked to fill out the questionnaire containing questions about low back pain, symptoms duration, all relevant inflammatory back pain parameters (according Calin and ASAS IBP criteria). Overall 3480 questionnaires were completed. <h3>Results</h3> The average age of respondents was 24±4,75 years; 76,35% of respondents were females. 1744 (50,1%) students reported having at least one episode of low back pain. 10,3% of all respondents (358), had chronic back pain. From 2657 interviewed 10,6% females had chronic low back pain, from 823 males 9,2%. 72 students (2, 1%) fulfilled ASAS IBP criteria, 48 (1.8%) females, 24 (2.9% males) respectively.101 (2,9%) respondents were defined as suffering inflammatory back pain according Calin criteria, 73 (2,7%) females and 28 (3.4%) males. The difference between prevalence of IBP among genders was not statistically significant. <h3>Conclusions</h3> In our study prevalence of inflammatory back pain among young people cohort was 2,1-2,9%, prevalence of chronic back pain – 10,3%. The data suggest that prevalence of inflammatory back pain did not differ significantly between young men and women. <h3>Acknowledgements</h3> Sieper, J. <i>et al</i>. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). <i>Ann. Rheum. Dis.</i> 68, 784–788 (2009). Calin, A. <i>et al</i>. Clinical history as a screening test for ankylosing spondylitis. <i>JAMA</i><b>237</b>, 2613–2614 (1977). <h3>Disclosure of Interest</h3> None Declared
Abstract 1376: TIMP-2 inhibits angiogenesis induced by tumor associated myeloid-suppressor cells
Authors: Liliana Guedez, William G. Stetler-Stevenson
Journal: Cancer Research (2012)

Abstract Among the mechanisms of resistance to cancer treatment is the recruitment by tumors of inflammatory myeloid (CD11b+, Gr-1+) suppressor cells, promoting angiogenesis and tumor progression. Here, we report the effects of tissue inhibitor of metalloproteases(TIMP)-2 on the recruitment of CD11b+, Gr-1+ cells and subsequent suppression of tumor angiogenesis. Previously, we showed that xenografts of A549 cells with up-regulated TIMP-2 demonstrated significant reduction in the number of CD11b+, Gr-1+ cells, expression of VEGF-R2, and αvβ3 as well as reduced angiogenesis. Here, the effect of TIMP-2 on the growth of Luciferase-tagged-A549 cells was tested in vivo using the direct in vivo angiogenesis (DIVA) assay implanted subcutaneously containing 400 nM TIMP-2 or PBS. TIMP-2 decreased A549-cell proliferation in vivo as determined by quantitating bioluminescence emission. Immuno-histochemistry analysis of the tissue in TIMP-2 treated DIVAs demonstrated a drastic reduction in inflammation, fewer CD11b+, Gr-1+ cells were recruited into the TIMP-2 DIVA compared with untreated DIVA controls, as well as significant lower number of angiogenic vessels and invading endothelial cells were seen. Moreover, bone marrow from mice carrying DIVA with TIMP-2-treated A549 cells demonstrated a relative decrease in cell progenitors as compared with PBS treated tumor cells, suggesting that TIMP-2 blocked the release of tumor factors affecting the mobilization of bone marrow progenitors. These findings support TIMP-2 as anti-angiogenesis and anti-inflammatory factor. By targeting tumor-myeloid suppressors cells, TIMP-2 may have a therapeutic utility in the resistance of tumors to angiogenesis inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1376. doi:1538-7445.AM2012-1376
CLINICAL OUTCOMES FOLLOWING CORONARY ARTERY BYPASS GRAFTING IN RELATION TO TIMING OF SURGERY FOLLOWING TICAGRELOR DISCONTINUATION: INSIGHTS FROM THE UNIVERSITY OF OTTAWA HEART INSTITUTE REGISTRY
Authors: Juan Russo, Tyler E. James, Nikita Malhotra, Daniel Goubran, Fraser Rubens, Michael Bourke, Jean-Yves Dupuis, Vincent Chan, Singh Kuljit, Marc Ruel, Benjamin Hibbert, Aun-Yeong Chong, Derek So
Journal: Journal of the American College of Cardiology (2016)
A novel device to improve colon cleanliness during colonoscopy
Authors: R. Eliakim, K. Yassin, J. Lachter, Y. Chowers
Journal: Endoscopy (2012)

<b>Background and study aim:</b> Effective colonoscopy depends on adequate visualization of the intestine, which might be ensured by intraprocedural use of a cleansing device. We investigated the performance of a novel endoscopic device with regard to cleanliness, safety, and tolerability during colonoscopy, compared with standard cleansing. <b>Patients and methods:</b> At a single center, colonoscopy patients in whom the cecum was accessed and at least one bowel segment was inadequately cleansed were assigned to either use of a disposable catheter cleansing device (JetPrep), used through the endoscope working channel, or standard manual cleansing using a 50-ml syringe. The cleansing quality, for each segment and before and after irrigation, was recorded using a 4-point scale ranging from excellent (grade 1, no more than small bits of adherent feces) to poor (grade 4, large amount of fecal residue). <b>Results:</b> 38 patients were included, 19 in each group. Reasons for referral included colorectal cancer screening (52 %), or blood loss (31 %). Each segment showed improvement after cleansing with JetPrep. Overall cleansing grade improved by a mean of 0.74 points (standard deviation [SD] 0.82) in the investigation group compared with 0.19 (0.40) in the control group (<i>P</i> < 0.0001), and right colon cleansing improved by 1.59 points (0.71) versus 0.31 (0.48) in the controls (<i>P</i> < 0.0001). There was no significant difference in procedure time between the groups. No adverse events or side effects were encountered. <b>Conclusions:</b> The JetPrep disposable catheter device is safe and efficient for intraprocedural cleansing of a suboptimally prepared colon, allowing higher quality colonoscopy.
INCIDENCE OF PACEMAKER IMPLANTATION AND PARAVALVULAR AORTIC INSUFFICIENCY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A COMPARISON OF THREE GENERATIONS OF EDWARDS SAPIEN VALVES
Authors: Paul Rogers, Ross Hoffman, Freddy Abi-samra, Michael Bernard, Sammy Khatib, Glenn Polin, Tyrone Collins, Stephen Ramee, Daniel Morin
Journal: Journal of the American College of Cardiology (2015)
A Pooled Analysis of Diagnostic Value of 99mTc-ubiquicidin (UBI) Scintigraphy in Detection of an Infectious Process
Authors: Sadeghi Ramin, Ayati Narjess, Aryana Kamran
Journal: Clinical Nuclear Medicine (2013)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Conflicts of interest and sources of funding: none declared. E-mail: [email protected]
Tc-99m Polyclonal Human Immunglobulin G Imaging in Graves’ Ophthalmopathy
Authors: H Durak, M Söylev, I Durak, B Değirmenci, G Capa Kaya, B Uysal
Journal: Clinical Nuclear Medicine (2000)

Purpose The authors evaluated the utility of Tc-99m–labeled human immunglobulin G (HIG) in determining the severity of orbital inflammation and the relation of orbital Tc-99m HIG uptake and clinical parameters in patients with Graves’ ophthalmopathy. Materials and Methods Images were obtained in 23 patients (13 women, 10 men; mean age, 51±10 years) with Graves’ ophthalmopathy. Planar orbital images were obtained and SPECT was performed using a triple-detector gamma camera 4 hours after 370 MBq (10 mCi) Tc-99m HIG injection. Tc-99m HIG uptake was classified using transaxial and coronal slices as 1, mild; 2, moderate; and 3, severe. The clinical severity of orbital disease was categorized, according to the criteria described by Feldon and Unsöld, as class I, mild involvement; class II, moderate; and class III, severe. Disease was considered to be clinically inactive if symptoms and signs were stable or improved in the last two examinations performed at least 6 months apart. Results Sixteen patients were clinically inactive, and seven patients were active. The mean Tc-99m HIG classes were 1.5±0.5 and 2.6±0.5, respectively (P = 0.02). There was not a good correlation between the clinical classification and Tc-99m HIG classification, whereas the presence of active disease showed a good correlation with Tc-99m HIG classification (r = 0.703; P = 0.0002). Conclusions Tc-99m HIG imaging showed possible ongoing subclinical inflammation in the orbits of the patients with Graves’ ophthalmopathy regardless of the clinical classification. Tc-99m HIG SPECT seems a promising procedure for evaluating the presence of active orbital inflammation.
La pertinence de l'indication de la coloscopie selon les critères de l'EPAGE II dans un centre hospitalier universitaire marocain
Authors: S Majdouli, S Majdouli, B Ihyane, G Ngatcha, T Adioui, F Safsafi, R Akka, O Lasri, S Ouahou, A Aourarh
Journal: Endoscopy (2012)

La pratique de l'endoscopie digestive est en augmentation constante. La coloscopie est l'examen de référence pour le diagnostic et la surveillance des polypes et des cancers colo-rectaux. Sa prescription doit être rationalisée tenant compte du rapport risque/bénéfice. Les critères de l'EPAGE (European Panel on the Appropriateness of gastrointestinal Endoscopy) permettent d'évaluer la pertinence des indications de la coloscopie. Aucune étude n'a évalué cette pertinence au Maroc. L'objectif de notre étude était d'évaluer l'application en pratique clinique des critères de l' EPAGE, tester la pertinence des indications de la coloscopie et rechercher une éventuelle corrélation entre la pertinence de l'examen et le résultat endoscopique.
IS LATE GADOLINIUM ENHANCEMENT MAGNETIC RESONANCE IMAGING NECESSARY FOR DETECTION OF TRANSMURAL SCAR TISSUE IN CHRONIC CORONARY ARTERY DISEASE PATIENTS WITH NEARLY NORMAL GLOBAL LEFT VENTRICULAR FUNCTION?
Authors: Assami Roesner, Derk Avenarius, Siri Malm, Amjid Iqbal, Bart Bijnens, Henrik Schirmer
Journal: Journal of the American College of Cardiology (2015)
Abstract 2514: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma
Authors: Rivera Zeyana, Soldano Ferrone, Xinhui Wang, Jube Sandro, Haining Yang, Giovanni Gaudino, Michele Carbone
Journal: Cancer Research (2012)

Abstract Malignant mesothelioma (MM) is an aggressive tumor, resistant to conventional therapies, with median survival of 1 year from diagnosis. The lack of effective therapies available prompted us to implement antibody-based immunotherapy against novel targets and to investigate possible synergies with chemotherapy on MM. CSPG4 is involved in the onset and progression of melanoma and other tumors, as well as in neo-angiogenesis. CSPG4-specific monoclonal antibodies (mAb) have shown anti-tumor effects in both preclinical and clinical trials of melanoma. We hypothesized that targeting CSPG4 with a CSPG4-specific mAb would have therapeutic efficacy against MM. We found that chondroitin sulphate proteoglycan 4 (CSPG4) was aberrantly expressed in 6 out of 8 MM cell lines and in 24 out of 40 MM biopsies, with minimal expression in surrounding non-malignant cells. The expression of CSPG4 in MM was higher upon engagement of extracellular matrix components (ECM) and was associated with increased MM cell viability and motility. Silencing of CSPG4 expression by siRNAs supported this functional significance of CSPG4 in MM. Consistently, the CSPG4-specific mAb TP41.2 inhibited MM cell attachment to the ECM, resulting in decreased phosphorylation of FAK and AKT, decreased expression of cyclin D1 and apoptosis. Moreover, TP41.2 significantly reduced MM cell motility, migration and invasiveness, and inhibited MM growth in soft agar. TP41.2 prevented the outgrowth of human MM tumors in SCID mice and inhibited the growth of established MM xenografts, resulting in significantly extended survival of tumor-bearing mice. These results represent a novel approach for CSPG4 mAb-based immunotherapy of MM. Combinatorial strategies with chemotherapeutic agents and with mAbs targeting c-Met related receptor are ongoing, aimed at translating CSPG4-specific mAb into clinical setting. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2514. doi:1538-7445.AM2012-2514
Abstract ADV04: Wisconsin Breast Cancer and the Environment Research Program.
Authors: Mary Pat Berry
Journal: Cancer Research (2013)

Abstract The Breast Cancer and Environmental Research Program was established by the NIH to better understand if and how a women's risk of developing breast cancer, is increased by impacted environmental carcinogens during key periods of her development. These periods are referred to as “Windows of Susceptibility.” UW-Madison is one of the eleven project collaborators. The UW-Madison Principal Investigators are Michael Gould and Amy Trentham-Dietz. Dr. Gould is focusing on genetics of supectibilty and resistance to breast cancer during periods of mammary development. His work is focused on areas of the DNA that may be associated with breast cancer. Dr. Trentham-Dietz is looking at environmental exposures that may be associated with breast cancer risk. The joint role of genetics and environmental factors research utilizes data on over 7,000 Wisconsin women. Once the Gould lab identifies genes that confer resistance of susceptibility, the Trentham-Dietz lab will use human DNA to actively identify similar genes in women. The Wisconsin project includes a particularly strong community partnership whose roles include giving input on the interests of women in the state. These community partners represent diverse organizations whose missions relate to breast cancer. The partners are: Wisconsin Cancer Council, the Breast Cancer Task Force of the WI Cancer Control Plan, Wisconsin Breast Cancer Coalition, Susan G. Komen- South Central Wisconsin Affiliate and the UW-Milwaukee Institute for Urban Health Partnerships. Together and with their distinct constituencies (health organizations, survivors, underserved populations, culturally diverse women, real women and advocates), these community partners do outreach for education relating to the program as well as for dissemination of the work being done at other sites as well as the UW-Madison. Citation Format: Mary Pat Berry. Wisconsin Breast Cancer and the Environment Research Program. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV04. doi:10.1158/1538-7445.AM2013-ADV04
Antenatal Betamethasone for Women at Risk for Late Preterm Delivery
Authors: Cynthia Gyamfi-Bannerman, Elizabeth A. Thom, Sean C. Blackwell, Alan T.N. Tita, Uma M. Reddy, George R. Saade, Dwight J. Rouse, David S. McKenna, Erin A.S. Clark, John M. Thorp, Edward K. Chien, Alan M. Peaceman, Ronald S. Gibbs, Geeta K. Swamy, Mary E. Norton, Brian M. Casey, Steve N. Caritis, Jorge E. Tolosa, Yoram Sorokin, J. Peter VanDorsten, Lucky Jain
Journal: New England Journal of Medicine (2016)

Infants who are born at 34 to 36 weeks of gestation (late preterm) are at greater risk for adverse respiratory and other outcomes than those born at 37 weeks of gestation or later. It is not known whether betamethasone administered to women at risk for late preterm delivery decreases the risks of neonatal morbidities. We conducted a multicenter, randomized trial involving women with a singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation who were at high risk for delivery during the late preterm period (up to 36 weeks 6 days). The participants were assigned to receive two injections of betamethasone or matching placebo 24 hours apart. The primary outcome was a neonatal composite of treatment in the first 72 hours (the use of continuous positive airway pressure or high-flow nasal cannula for at least 2 hours, supplemental oxygen with a fraction of inspired oxygen of at least 0.30 for at least 4 hours, extracorporeal membrane oxygenation, or mechanical ventilation) or stillbirth or neonatal death within 72 hours after delivery. The primary outcome occurred in 165 of 1427 infants (11.6%) in the betamethasone group and 202 of 1400 (14.4%) in the placebo group (relative risk in the betamethasone group, 0.80; 95% confidence interval [CI], 0.66 to 0.97; P=0.02). Severe respiratory complications, transient tachypnea of the newborn, surfactant use, and bronchopulmonary dysplasia also occurred significantly less frequently in the betamethasone group. There were no significant between-group differences in the incidence of chorioamnionitis or neonatal sepsis. Neonatal hypoglycemia was more common in the betamethasone group than in the placebo group (24.0% vs. 15.0%; relative risk, 1.60; 95% CI, 1.37 to 1.87; P<0.001). Administration of betamethasone to women at risk for late preterm delivery significantly reduced the rate of neonatal respiratory complications. (Funded by the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT01222247.).
SP0144 The wider impact of chronic diseases on family and society - from the carer’s perspective
Authors: H. Döhner
Journal: Annals of the Rheumatic Diseases (2013)

Eurocarers is a European association representing informal carers and their organisations, with the aim to advance their interests, irrespective of the particular age or health need of the person they are caring for. Carers are defined as persons who provide care (usually unpaid) to someone with a chronic illness, disability or other long lasting health or care need. Informal care is the preferred option of care by most European citizens. Consequently family care is the main source of support and help for different needs - emotional, physical, organisational and financial. Newest research is reporting about ca. 100 million carers in the EU of today. Including the enlarged EU, estimations amount to some 125 million carers in Europe. Although many carers talk about positive aspects of caring, most of them are more or less burdened, including objective and subjective elements. The amount of burden depends on different factors: e.g. the degree of dependency of the person cared-for, the appreciation felt, the received support, the possibility to combine care and paid work. Carers are in high risk to get ill themselves. If the dependent person has cognitive impairments, especially in case of dementia including behavioral problems, the burden is especially high. In these cases carers additionally have a high risk of social isolation. More and more national carers organisations are on the way to bring the immense societal work of carers and the enormous economical value on the political agenda. The political awareness of the high amount of support families are giving to their relatives in need and the measures made available by professional offers varies a lot across Europe, with more formal support in Northern countries than in South and East Europe. Eurocarers will help to make the situation more visible all over Europe and to push developments for a better quality of life for carers as a prerequisite for the wellbeing of the cared-for. <h3>Disclosure of Interest</h3> None Declared
Characterization of Environmental Risk Factors Among Inner-City Schoolchildren with Physician Diagnosed Asthma from the Pittsburgh Region
Authors: Paige E. Dewhirst, Jennifer Paden Elliott, Albert Presto, Tricia Morphew, Erica Butler, Nicole Pleskovic, David P. Skoner, Deborah A. Gentile
Journal: Journal of Allergy and Clinical Immunology (2016)